2019年1月10日（周四）14:00 – 15:00 p.m.
Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, and potentially, other cell types. It's thought to be the basis of tissue regeneration. However, the therapeutic application of mesenchymal stem cell has also been revealed some problems. Studies have shown that about 90 percent of mesenchymal stem cells amplified in 2D culture are blocked in pulmonary microvessels after intravenous injection. But 3D-cultured mesenchymal stem cells have been shown to significantly reduce pulmonary Vascular obstruction after intravenous transplantation. Compared with 2D mesenchymal stem cells, 3D mesenchymal stem cells have several advantages for clinical use and have an enhanced therapeutic effect. Therefore, using Mesenchymal stem cells three dimensional cultures for various types of disease treatment is quite promising. This presentation discusses the comprehensive understandings of 3D MSC, as well as the current trends and the challenges in this field.
Miaohua Mo, received her Ph.D. degree in Stem Cells Biology, Tsinghua University in July, 2018, after which she joined TBSI in lab 3D as a postdoctoral fellow in September, 2018, supervised by Prof. Yaojiong Wu and Prof. Ting Xu. Her research interest is to optimize 3D mesenchymal stem cells culture systems. In particular, She is working on the mechanism of 3D MSC with enhanced therapeutic efficacy and the decreasing cell size in 3D MSC , as well as MSC-based skin tissue engineering.